Enoxaparin sodium
- Generic Name
- Enoxaparin sodium
- Brand Names
- Lovenox, Inhixa
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- 9005-49-6
- Unique Ingredient Identifier
- E47C0NF7LV
- Background
Enoxaparin is a common low-molecular-weight heparin (LMWH) used in the prevention and management of various thromboembolic disorders. Initially approved by the FDA in 1993, it is administered by a subcutaneous or intravenous injection and marketed by several pharmaceutical companies. Enoxaparin markedly reduces the incidence of venous thromboembolism in hosp...
- Indication
Enoxaparin is indicated for the prevention of ischemic complications in unstable angina and in non Q-wave myocardial infarction; it is indicated in conjunction with percutaneous intervention and/or other treatment for the management of acute ST elevation myocardial infarction.
...
- Associated Conditions
- Acute Coronary Syndrome (ACS), Acute Myocardial Infarction With ST Segment Elevation, Deep Vein Thrombosis, Ischemic complications caused by non-q wave myocardial infarction, Ischemic complications caused by unstable angina
- Associated Therapies
- Percutaneous Coronary Intervention (PCI)
Michelangelo - Oasis 5
- First Posted Date
- 2005-08-31
- Last Posted Date
- 2016-09-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 20078
- Registration Number
- NCT00139815
Which Therapy for Acute Heart Attacks? (The WEST Study)
- Conditions
- First Posted Date
- 2005-07-21
- Last Posted Date
- 2017-05-19
- Lead Sponsor
- University of Alberta
- Target Recruit Count
- 300
- Registration Number
- NCT00121446
- Locations
- 🇨🇦
Queen Elizabeth II Hospital, Halifax, Nova Scotia, Canada
🇨🇦Grey Nuns Community Hospital, Edmonton, Alberta, Canada
🇨🇦Misericordia Hospital, Edmonton, Alberta, Canada
BMS-562247 in Subjects Undergoing Elective Total Knee Replacement Surgery
- Conditions
- Interventions
- First Posted Date
- 2004-11-23
- Last Posted Date
- 2010-03-02
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1238
- Registration Number
- NCT00097357
- Locations
- 🇵🇷
Local Institution, Ponce, Puerto Rico
Heparin or Enoxaparin in Patients With Cancer
- Conditions
- Interventions
- First Posted Date
- 2004-07-26
- Last Posted Date
- 2011-02-21
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 6
- Registration Number
- NCT00004875
- Locations
- 🇺🇸
Veterans Affairs Medical Center - Chicago (Lakeside), Chicago, Illinois, United States
🇺🇸Evanston Northwestern Health Care, Evanston, Illinois, United States
Safety and Efficacy of Enoxaparin in Percutaneous Coronary Intervention (PCI) Patients, an International Randomized Evaluation (STEEPLE)
- Conditions
- First Posted Date
- 2004-02-18
- Last Posted Date
- 2011-01-11
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 3532
- Registration Number
- NCT00077844
PREVAIL: PREvention of VTE After Acute Ischemic Stroke With LMWH Enoxaparin ( - VTE: Venous Thromboembolism - LMWH: Low Molecular Weight Heparin)
- Conditions
- First Posted Date
- 2004-02-16
- Last Posted Date
- 2011-01-11
- Lead Sponsor
- Sanofi
- Registration Number
- NCT00077805
- Locations
- 🇹🇷
Sanofi-Aventis, Istanbul, Turkey
EXCLAIM:Extended Prophylaxis for Venous ThromboEmbolism (VTE) in Acutely Ill Medical Patients With Prolonged Immobilization
- Conditions
- First Posted Date
- 2004-02-16
- Last Posted Date
- 2011-01-11
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 4726
- Registration Number
- NCT00077753
- Locations
- 🇬🇧
Sanofi-Aventis, Guildford, United Kingdom
Enoxaparin Versus Unfractionated Heparin in Subjects Who Present to the Emergency Department With Acute Coronary Syndrome (RESCUE)
- Conditions
- First Posted Date
- 2004-02-16
- Last Posted Date
- 2009-10-15
- Lead Sponsor
- Sanofi
- Registration Number
- NCT00077818
New Oral Anticoagulant Therapy for the Prevention of Blood Clots Following Hip or Knee Replacement Surgery
- Conditions
- Interventions
- First Posted Date
- 2003-12-23
- Last Posted Date
- 2008-03-31
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 511
- Registration Number
- NCT00074828
- Locations
- 🇵🇱
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Bydgoszcz, Poland
SYNERGY: Open Study of Enoxaparin Versus Unfractionated Heparin in Patients With Acute Coronary Syndromes
- Conditions
- First Posted Date
- 2002-08-15
- Last Posted Date
- 2008-09-16
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 8000
- Registration Number
- NCT00043784
- Locations
- 🇺🇸
Duke Clinical Research Institute, Durham, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.